Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is now covered by analysts at Ascendiant Capital Markets. They set a "buy" rating and a $2.60 price target on the stock.
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease [Yahoo! Finance]